Afnet Redakteur

AI-driven analysis of atrial fibrillation burden in pacemaker patients reveals no effect of AF burden on stroke

by

An analysis of the NOAH – AFNET 6 trial used large language models to extract AF burden from pacemaker data in patients with device-detected atrial fibrillation. This approach enables to evaluate the impact of AF burden on cardiovascular outcome and on the effectiveness and safety of anticoagulation in pacemaker patients. The AF burden in the population was 0.4%, with 20% of patients showing a baseline AF burden of more than 1%. In these patients, there was no effect of AF burden on stroke or other cardiovascular events. Today, the findings were presented by AFNET board member Prof. Ulrich Schotten, Maastricht, as a hotline at the Heart Rhythm congress 2026 in Chicago (1).

3rd AFNET DGK Young Investigator Award – Atrial Fibrillation 2026

by

Once again, four young scientists were honored with the AFNET-sponsored “DGK AFNET Young Investigator Award” for their current research on atrial fibrillation. AFNET Board Member and this year’s DGK Conference President Prof. Dr. Stephan Willems congratulated the award recipients during the award ceremony on April 10, 2026 at the DGK Annual Congress.

3rd AFNET Lecture Award 2026

by

As part of the “23 Years of AFNET” session, Prof. Steinbeck presented the AFNET Lecture titled “EP Studies Revisited.” For his long-standing commitment, he received this year’s DGK-AFNET Lecture Award, which was presented for the third time. Prof. Sinner presented the results of the 10th AFNET-EHRA Consensus Conference.

ESC Congress 2026

by

The ESC Congress 2026 will take place from August 29 to September 1, 2026, in Munich, Germany, at the International Congress Center Munich (ICM).

SKY AF Summit

by

Unter der Schirmherrschaft von AFNET und DGK findet am 27. Mai 2026 der SKY AF Summit (Frankfurt am Main & online) statt – eine internationale wissenschaftliche Veranstaltung mit einem facettenreichen Programm.
Im Fokus stehen die jüngsten Fortschritte im Verständnis und in der Behandlung des Vorhofflimmerns.

Kidney disease increases the risk of cardiovascular events in patients with device-detected atrial fibrillation

by

A prespecified analysis of the NOAH – AFNET 6 trial investigated the impact of kidney function on cardiovascular outcome in patients with device-detected atrial fibrillation. Today, the findings were presented by AFNET board member Prof. Andreas Goette, St. Vincenz Hospital, Paderborn, Germany, at the annual congress of the European Heart Rhythm Association (EHRA) in Paris and published in the EP Europace journal (1,2).